Menu Search
Equities

aTyr Pharma Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
471A:DUS

aTyr Pharma Inc

Actions
  • Price (EUR)0.725
  • Today's Change0.01 / 1.40%
  • Shares traded13.50k
  • 1 Year change-79.17%
  • Beta0.5712
Data delayed at least 15 minutes, as of Feb 12 2026 18:32 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase-derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and potentially prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0750 is a fusion protein derived from the domain of alanyl-tRNA synthetase (AARS). ATYR0750 is a novel ligand to fibroblast growth factor receptor 4 (FGFR4).

  • Revenue in USD (TTM)190.00k
  • Net income in USD-75.12m
  • Incorporated2005
  • Employees56.00
  • Location
    aTyr Pharma Inc10240 Sorrento Valley Road, Suite 300SAN DIEGO 92121United StatesUSA
  • Phone+1 (858) 731-8389
  • Fax+1 (858) 731-8394
  • Websitehttps://www.atyrpharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.